NovoCure Limited (NVCR)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in NovoCure Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

NovoCure Limited (NVCR) has returned -15.70% so far this year and -38.83% over the past 12 months. Over the last ten years, NVCR has returned -2.56% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Oct 2, 2015, NVCR's average daily return is +0.08%, while the average monthly return is +1.59%. At this rate, your investment would double in approximately 3.7 years.

Historically, 48% of months were positive and 52% were negative. The best month was May 2024 with a return of +79.8%, while the worst month was Jan 2016 at -44.2%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 7 months.

On a daily basis, NVCR closed higher 49% of trading days. The best single day was Jan 5, 2023 with a return of +68.5%, while the worst single day was Jun 6, 2023 at -43.0%.

NovoCure Limited has an annualized alpha of 4.79%, beta of 1.25, and R² of 0.09 versus S&P 500 Index. Calculated based on daily prices since October 05, 2015.

• This stock participated in 147.61% of S&P 500 Index downside but only 75.04% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.09 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

NVCR ranks 15 for risk / return — in the bottom 15% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for NovoCure Limited (NVCR) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the NovoCure Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the NovoCure Limited was 95.55%, occurring on Feb 9, 2026. The portfolio has not yet recovered.

The current NovoCure Limited drawdown is 95.17%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of NovoCure Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how NovoCure Limited is priced in the market compared to other companies in the Medical Instruments & Supplies industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.